Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells

Eur J Cancer. 2007 Jul;43(10):1581-9. doi: 10.1016/j.ejca.2007.03.003. Epub 2007 Apr 18.

Abstract

Central nervous system (CNS) atypical teratoid/rhabdoid tumours (AT/RT) are among the paediatric malignant tumours with the worst prognosis and fatal outcome. Insulin-like growth factor I receptor (IGF-IR) protects cancer cells from apoptosis induced by a variety of anticancer drugs and radiation. In the present study, IGF-IR was expressed in 8/8 primary AT/RT as detected by immunohistochemistry. Moreover, we found IGF-I and IGF-II mRNA in BT-16 CNS AT/RT cells and IGF-II mRNA in BT-12 CNS AT/RT cells, and autophosphorylated IGF-IR in both cell lines, indicating the potential presence of an autocrine/paracrine IGF-I/II/IGF-IR loop in CNS AT/RT. IGF-IR antisense oligonucleotide treatment of human CNS AT/RT cells resulted in significant down-regulation of IGF-IR mRNA and protein expression, induction of apoptosis, and chemosensitisation to doxorubicin and cisplatin. These studies provide evidence for the influence of IGF-IR on cellular responses to chemotherapy and raise the possibility that curability of selected CNS AT/RT may be improved by pharmaceutical strategies directed towards the IGF-IR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects*
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / pathology
  • Child
  • Child, Preschool
  • Cisplatin / therapeutic use
  • Down-Regulation
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Infant
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Oligoribonucleotides, Antisense / therapeutic use*
  • Receptor, IGF Type 1 / drug effects*
  • Receptor, IGF Type 1 / metabolism
  • Rhabdoid Tumor / drug therapy*
  • Rhabdoid Tumor / pathology
  • Teratoma / drug therapy*
  • Teratoma / pathology

Substances

  • Antineoplastic Agents
  • Oligoribonucleotides, Antisense
  • Insulin-Like Growth Factor I
  • Doxorubicin
  • Receptor, IGF Type 1
  • Cisplatin